DeepMed Research

Gustave Roussy, Cancer Campus, Grand Paris

🇫🇷France

Country: 🇫🇷France

Ownership: Private

Employees: -

Market Cap: -

Website

Clinical Trials

Trial of Ipilimumab After Isolated Limb Perfusion, in Patients With Metastases Melanoma

Phase 2

Completed

Conditions: In-transit Metastases Melanoma Stage IIIB and IIIC

Interventions: Drug: Ipilimumab

First Posted Date: 2014-03-21

Last Posted Date: 2016-06-09

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 4

Registration Number: NCT02094391

Locations: 🇫🇷
Gustave Roussy Cancer Campus Grand Paris, Villejuif, Val de Marne, France

Trial of Superiority of Stereotactic Body Radiation Therapy in Patients With Breast Cancer

Phase 3

Recruiting

Conditions: Breast Cancer

Interventions: Radiation: stereotactic body radiation therapy
Radiation: Systemic treatment

First Posted Date: 2014-03-17

Last Posted Date: 2024-08-15

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 280

Registration Number: NCT02089100

Locations: 🇫🇷
Gustave Roussy Cancer Campus Grand Paris, Villejuif, Val De Marne, France

Measurement of Cardiac Index Using an Implanted Central Venous Access Port in Patients Scheduled for Oncologic High-risk Surgery

Completed

Conditions: Oncologic High-risk Surgery

First Posted Date: 2014-02-14

Last Posted Date: 2014-02-14

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 33

Registration Number: NCT02063009

Locations: 🇫🇷
Gustave Roussy Cancer Campus Grand Paris, Villejuif, Val de Marne, France

Patient Preference Between Cabazitaxel and Docetaxel in Metastatic Castrate-resistant Prostate Cancer

Phase 3

Conditions: Metastatic Castration-resistant Prostate Cancer

Interventions: Drug: Taxotere
Drug: Jevtana

First Posted Date: 2014-01-24

Last Posted Date: 2017-08-08

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 195

Registration Number: NCT02044354

Locations: 🇫🇷
Gustave Roussy, Villejuif, Val de Marne, France

Tolerability and Efficacy of Tremelimumab in Combination With Gefitinib in NSCLC Patients

Phase 1

Completed

Conditions: Non Small Cell Lung Cancer

Interventions: Drug: Gefitinib
Drug: Tremelimumab

First Posted Date: 2014-01-20

Last Posted Date: 2016-06-09

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 27

Registration Number: NCT02040064

Locations: 🇫🇷
Gustave Roussy, Villejuif, Val de Marne, France

Study of Sequential High-dose Chemotherapy in Children With High Risk Medulloblastoma

Phase 1

Terminated

Conditions: High-risk Medulloblastoma

Interventions: Drug: Carboplatin + etoposide
Drug: Thiotepa
Drug: Cyclophosphamide + Busilvex
Drug: Temozolimide + Irinotecan
Combination Product: Etoposide + radiotherapy
Drug: Temozolomide

First Posted Date: 2014-01-01

Last Posted Date: 2024-05-24

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 29

Registration Number: NCT02025881

Locations: 🇫🇷
Centre Léon Bérard, Lyon, France
🇫🇷
Gustave Roussy, Villejuif, Val De Marne, France
🇫🇷
Centre Oscar Lambret, Lille, France

and more 10 locations

A Phase Ib Study of the Safety, Tolerability and Efficacy of LY2780301 in Combination With Gemcitabine

Phase 1

Completed

Conditions: Solid Tumors and Non-Hodgkin's Lymphoma

Interventions: Drug: LY2780301
Drug: Gemcitabine

First Posted Date: 2013-12-23

Last Posted Date: 2016-07-12

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 52

Registration Number: NCT02018874

Locations: 🇫🇷
Gustave Roussy, Villejuif, Val de Marne, France

Randomized Phase II Study to Assess PD 0332991 in Breast Cancer

Phase 2

Completed

Conditions: Untreated Operable Early Breast Cancer

Interventions: Drug: PD0332991

First Posted Date: 2013-12-11

Last Posted Date: 2016-06-09

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 132

Registration Number: NCT02008734

Locations: 🇫🇷
Gustave Roussy, Villejuif, Val de Marne, France

Study of Vinblastine in Combination With Nilotinib in Children, Adolescents, and Young Adults

Phase 2

Terminated

Conditions: Refractory Low-grade Gliomas
Recurrent Low-grade Gliomas

Interventions: Drug: Vinblastine + Nilotinib
Drug: Vinblastine

First Posted Date: 2013-06-27

Last Posted Date: 2022-05-31

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 144

Registration Number: NCT01887522

Locations: 🇦🇹
Medical University of Vienna, Vienna, Austria
🇨🇭
Swiss Pediatric Oncology Group, Bern, Switzerland
🇬🇧
Cancer Research UK Clinical Trials Unit School of Cancer Sciences University of Birmingham, Edgbaston, Birmingham, United Kingdom

and more 5 locations

Assessing Everolimus in Fist Line Treatment on Patients With Metastatic Kidney Cancer

Phase 2

Terminated

Conditions: Kidney Cancer

Interventions: Drug: Everolimus

First Posted Date: 2013-06-27

Last Posted Date: 2016-02-10

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 61

Registration Number: NCT01888042

Locations: 🇫🇷
Gustave Roussy, Villejuif, Val de Marne, France

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy